JPRN-UMIN000032064已完成未知
A pilot traial of False Safety Behavior Elimination Therapy for Social Anxiety Disorder. - A piloy traial of False Safety Behavior Elimination Therapy for social anxiety Disorder.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •psychosis, major depression, bipolar, active suicidality, organic brain disorder, substance abuse or dependence, antisocial personality disorder, other severe mental / physical condition
研究者
相似试验
进行中（未招募）
不适用
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-ATIntercept Pharmaceuticals Inc78
进行中（未招募）
不适用
An Early Stage Study to Evaluate the Safety, Tolerability and Efficacy of the Medicinal Product Obeticholic Acid for the Treatment of Portal Hypertension, a liver disease.EUCTR2010-023241-29-GBIntercept Pharmaceuticals Inc78
进行中（未招募）
1 期
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-BEIntercept Pharmaceuticals Inc78
终止
1 期
A pilot study of Lewis-Y targeting Chimeric Antigen Receptor T-cells given in combination with Nivolumab in Lewis-Y expressing solid tumours.ACTRN12622001542785Peter MacCallum Cancer Centre4
进行中（未招募）
不适用
A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIENTS WITH METASTASIZED PROSTATE CARCINOMA AND A LIFE EXPECTANCY OF AT LEAST 6 MONTHS.Patients suffering from prostate carcinoma with progression underfirst line hormonal treatment. Patients entering the study shouldhave a life expectancy prognosis of at least 6 months.MedDRA version: 12.1Level: LLTClassification code 10007453Term: Carcinoma of the prostate metastaticEUCTR2010-020681-16-DEunamed Operations AG